MedTrace Logo

Neuroprotection During Open Heart Surgery

NCT04486690 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-07-24

No results posted yet for this study

Summary

Millions of individuals with coronary artery, or valvular heart disease have been given a new chance at life by heart surgery, but the potential for neurological injury is a great risk .Neural complications - including neurocognitive dysfunction and ischemic complications are complications of cardiac surgery that can restrict the improved quality of life.

Propofol is one of the most popular agents used for induction of anesthesia. propofol reduces cerebral blood flow but maintains coupling with cerebral metabolic rate for oxygen and decreases intracranial pressure, allowing optimal intraoperative conditions.

Ketamine is a non-competitive antagonist of NMDA receptors that has well documented neuroprotective effects against ischemic brain injury and glutamate-induced brain injury. ketamine has neuroprotective effects against oxygen-glucose deprivation injury

Conditions

  • Open Heart Surgery

Interventions

DRUG

Ketofol (propofol to ketamine ratio 1:1)

* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1. * Fentanyl infusion, 1-2 mcg/kg/h. * Atracurium infusion, 3-12 mic/kg/min

DRUG

propofol

Propofol infusion, 25-150 mcg/kg/min. * Fentanyl infusion, 1-2 mcg/kg/h. * Atracurium infusion, 3-12 mic/kg/min.

Sponsors & Collaborators

  • ghada fouad

    lead OTHER

Principal Investigators

  • mona a hashish, M.D · professor of anesthesia

  • ahmed m elshamy, master · assistant lecturer of anesthesia

  • ghada f amer, M.D · associate professor of anesthesia

  • magdy m attalaha, M.D · professor of anethesia

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2017-06-30
Completion
2017-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04486690 on ClinicalTrials.gov